Low‐dose valganciclovir for cytomegalovirus prophylaxis in intermediate‐risk liver transplantation recipients

Salman Khan, Timothy Sullivan, Mohsin Ali, Dallas Dunn, Gopi Patel, Shirish Huprikar – 3 March 2018 – Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus (CMV) (recipient seropositive [R+]) are at intermediate risk for CMV disease. A preventative strategy following transplant is considered standard of care. Current guidelines recommend high‐dose valganciclovir (VGCV; 900 mg/day adjusted for renal function) for prophylaxis given limited data on the efficacy and safety of low‐dose VGCV (450 mg/day adjusted for renal function).

Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury

Marina Gazdic, Bojana Simovic Markovic, Aleksandar Arsenijevic, Nemanja Jovicic, Aleksandar Acovic, C. Randall Harrell, Crissy Fellabaum, Valentin Djonov, Nebojsa Arsenijevic, Miodrag L. Lukic, Vladislav Volarevic – 3 March 2018 – One of the therapeutic options for the treatment of fulminant hepatitis is repopulation of intrahepatic regulatory cells because their pool is significantly reduced during acute liver failure.

Alterations in gut microbial function following liver transplant

Jasmohan S. Bajaj, Genta Kakiyama, I. Jane Cox, Hiroshi Nittono, Hajime Takei, Melanie White, Andrew Fagan, Edith A. Gavis, Douglas M. Heuman, Ho Chong Gilles, Phillip Hylemon, Simon D. Taylor‐Robinson, Cristina Legido‐Quigley, Min Kim, Jin Xu, Roger Williams, Masoumeh Sikaroodi, William M. Pandak, Patrick M. Gillevet – 3 March 2018 – Liver transplantation (LT) improves daily function and ameliorates gut microbial composition. However, the effect of LT on microbial functionality, which can be related to overall patient benefit, is unclear and could affect the post‐LT course.

Subscribe to